Molnupiravir 200 Mg Capsules.

Molnupiravir is indicated for treatment of mild to moderate coronavirus disease (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and whMolnupiravir is the oral prodrug of beta-D-N4-hydroxycytidine (NHC), a ribonucleoside that has shown antiviral activity against SARS-CoV-2 in vitro and in clinical trials.1,2 NHC uptake by viral RNA-dependent RNA-polymerases results in viral mutations and lethal mutagenesis.3,4 On December 23, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for molnupiravir for the treatment of adults with mild to moderate COVID-19 who are within 5 days of symptom onset, who are at high risk of progressing to severe disease, and for whom alternative antiviral therapies are not accessible or clinically appropriate.5,6
As a mutagenic ribonucleoside antiviral agent, there is a theoretical risk that molnupiravir will be metabolized by the human host cell and incorporated into the host DNA, leading to mutations. Molnupiravir has been evaluated in 2 in vivo rodent mutagenicity assays. One study produced equivocal results. In the other study, there was no evidence for mutagenicity.6 The FDA concluded that, based on the available genotoxicity data and the 5-day duration of treatment, molnupiravir has a low risk for genotoxicity.6In addition, there have been concerns about the potential effects of molnupiravir on SARS-CoV-2 mutation rates; the FDA has required that the manufacturer monitor genomic databases for the emergence of SARS-CoV-2 variants.o have at least one risk factor for developing severe illness1